[The effect of dipyridamole on the results of allogenic kidney transplantation].
In a prospective randomized trial the anti-thrombotic effect of dipyridamole was studied in 64 patients after cadaveric kidney allotransplantation. The frequency of early graft function was significantly higher in the control group, whereas the incidence of arterial and venous thromboses were not different. One-year graft survival could not be improved by dipyridamole. Therefore, dipyridamole should not be recommended in cadaveric kidney allotransplantation.
Klinik und Poliklinik für Urologie, Bereiches Medizin der Martin-Luther-Universität Halle-Wittenberg.
R
R
Schulze
B
B
Langkopf
W
W
Sziegoleit
D002102:Cadaver; D004176:Dipyridamole / Q000627:therapeutic use*; D006083:Graft Occlusion, Vascular / Q000188:drug therapy*; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D007262:Infusions, Intravenous; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000276:immunology*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012077:Renal Artery / Q000601:surgery; D012082:Renal Veins / Q000601:surgery
D004176:Dipyridamole
Der Einfluss von Dipyridamol auf die Ergebnisse der allogenen Nieren-transplantation.